Skip to content

Accuracy Validation of an Artificial Intelligence Recognition Technique on Non-contrast Esophageal CT in High-Risk Population Screening

Accuracy Validation of an Artificial Intelligence Recognition Technique on Non-contrast Esophageal CT in High-Risk Population Screening

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127047
Enrollment
Unknown
Registered
2026-06-23
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Interventions

Gold Standard:Upper gastrointestinal endoscopy
surgical or biopsy pathology For those in whom the gold standard could not be obtained for various reasons, the absence of symptoms such as retrosternal pain and dysphagia during telephone follow-up w
Index test:Artificial intelligence-assisted detection model for malignant esophageal lesions based on non-contrast chest CT — EAGLE (Esophageal AI-Guided malignant Lesion Evaluation)

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients who undergo non-contrast chest CT examination for various reasons in the four major hospital settings (outpatient, emergency, inpatient, and health checkup); 2.Age > 18 years.

Exclusion criteria

Exclusion criteria: 1.Chest CT examinations that do not cover the entire esophagus; 2.Non-standard scans (e.g., hands placed on both sides of the body or over the upper abdomen, large respiratory motion artifacts, perfusion contamination, etc.); 3.Presence of other metal artifacts (e.g., from cardiac stents) that may potentially affect interpretation; 4.Patients with prior thoracic/abdominal surgery or therapeutic procedures that alter or change the anatomical appearance of the esophagus (e.g., post-esophageal/gastric/cardiac/vascular/ERCP procedures, etc.); 5.Patients with a definite history of esophageal or gastric cancer or those undergoing post-treatment follow-up; 6.Patients with upper gastrointestinal perforation, massive ascites, severe abdominal distension, or severe esophageal varices; Pregnant women.

Design outcomes

Primary

MeasureTime frame
sensitivity;specificity;Positive Predictive Value;

Countries

China

Contacts

Public ContactKai Cao

Shanghai Changhai Hospital

mdkaicao163@163.com+86 185 0211 3743

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026